Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 99

Sort by

Sort Order Select

Journal Articles

FLT3-ITD drives poor prognosis in NPM1 mutated AML via BCAT1-dependent epigenetic regulation

Kainan Zhang, Xiaohang Ma, Xiaoxuan Lu, Guorui Ruan, Fangfang Wei, Hao Jiang, Xiaojun Huang, Xiaosu Zhao

Blood (2025) 146 (Supplement 1): 5003.

https://doi.org/10.1182/blood-2025-5003

Published: 2025

Journal Articles

IDH1/2 mutations predict a distinct high-risk subset in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia

Lijuan Hu, Sheng-Ye Lu, Lu Yu, Zongru Li, Hao Jiang, Xiaohui Zhang, Lanping Xu, Yu Wang, Qian Jiang, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 3374.

https://doi.org/10.1182/blood-2025-3374

Published: 2025

Journal Articles

Thrombopoietin receptor agonists combined with intensive immunosuppressive therapy improve outcomes in elderly patients with severe aplastic anemia: A single-center retrospective study

Jinsong JIA, Bo Shao, Xiaofei Jia, Cao Qin, Hao Jiang, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 1119.

https://doi.org/10.1182/blood-2025-1119

Published: 2025

Journal Articles

Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML

Guanghui Chang, Haitao Gao, Qiang Fu, Xiaosu Zhao, Yu Wang, Qian Jiang, Hao Jiang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Feifei Tang

Blood (2025) 146 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2025-5163

Published: 2025

Journal Articles

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Blood (2025) 146 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2025-5162

Published: 2025

Journal Articles

Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study

Wen-Jing Yu, Wen-Bing Duan, Qi Chen, Xuying Pei, Jinsong JIA, Jing Wang, Xiaolu Zhu, Xiaosu Zhao, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2025-1680

Published: 2025

Journal Articles

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial

Xiaolu Zhu, Zhao Ting, Wen-Bing Duan, Qi Chen, Jing Liu, Wen-Jing Yu, Xiaosu Zhao, Ya-Zhen Qin, Hong-Xia Shi, Ying-Jun Chang, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1671.

https://doi.org/10.1182/blood-2025-1671

Published: 2025

Journal Articles

Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia

Shunjie Yu, Zongru Li, Lijuan Hu, Ya-Zhen Qin, Guorui Ruan, Yazhe Wang, Hao Jiang, Feifei Tang, Jinsong JIA, Jing Wang, Qiang Fu, Xiaohui Zhang, Lanping Xu, Yu Wang, Yuqian Sun, Yueyun Lai, Hong-Xia Shi, Xiaojun Huang, Qian Jiang

Blood (2025) 146 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2025-3400

Published: 2025

Journal Articles

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Wenbing Duan, Ying Wu, Wen-Jing Yu, Qi Chen, Zhao Ting, Jing Liu, Le-Qing Cao, Ying-Jun Chang, Xiaosu Zhao, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 1611.

https://doi.org/10.1182/blood-2025-1611

Published: 2025

Journal Articles

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia

Wenbing Duan, Qi Chen, Wen-Jing Yu, Xiaolu Zhu, Jing Liu, Zhao Ting, Xiaosu Zhao, Ya-Zhen Qin, Guorui Ruan, Ying-Jun Chang, Xiaojun Huang, Hao Jiang

Blood (2025) 146 (Supplement 1): 6966.

https://doi.org/10.1182/blood-2025-6966

Published: 2025

Journal Articles

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Jianxiang Wang, Guanchen Bai, Pengcheng He, Hao Jiang, Fuling Zhou, Wei Yang, Xingli Zhao, Shuning Wei, Zhen Wang, Wenwei Zhu, Lin Geng, Zhihua Zhang, Jianhua Qu, Jie Zhou, Tiejun Gong, Ligen Liu, Junfeng Zhu

Blood (2025) 146 (Supplement 1): 5196.

https://doi.org/10.1182/blood-2025-5196

Published: 2025

Journal Articles

Integrating EVI1 expression into prognostic models for MDS: Insights from IPSS-R and IPSS-m subgroup analyses

Xiaohang Ma, Wen-Bing Duan, Qi Chen, Ya-Zhen Qin, Hao Jiang, Qian Jiang, Ying-Jun Chang, Xiaojun Huang, Xiaosu Zhao

Blood (2025) 146 (Supplement 1): 3479.

https://doi.org/10.1182/blood-2025-3479

Published: 2025

Journal Articles

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Meng Lv, Hao Jiang, Yuhua Li, Yicheng Zhang, Jie Jin, Hongsheng Zhou, Kailin Xu, Mingfeng Zhao, Xin Du, Kai Hu, Jun Hu, Jinghua Zhao, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2025-1563

Published: 2025

Journal Articles

Clinical efficacy and diagnostic value of metagenomic next-generation sequencing for pathogen detection in severe aplastic anemia patients with suspected infectious diseases

Jinsong JIA, Xiaojing Zhang, Bo Shao, Xiaofei Jia, Hao Jiang, Xiaojun Huang

Blood (2025) 146 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2025-2894

Published: 2025

Journal Articles

Hypoxia-driven complement activation expands circulating endothelial cells in transplant-associated thrombotic microangiopathy: A multi-omics single-cell and functional study

Jiaqian Qi, Yan Zhang, Lijun Zhou, Liangliang Wang, Shuhui Jiang, Xin Ye, Guocai Mao, Xuedong Wei, Yuhuang Huang, Linkun Hu, Han Yue, Hao Jiang

Blood (2025) 146 (Supplement 1): 199.

https://doi.org/10.1182/blood-2025-199

Published: 2025

Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2024-209768

Published: 2024

Journal Articles

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Wenbing Duan, Chunkang Chang, Zhiguo Wang, Hongbing Ma, Min Ouyang, Xingli Zhao, Lifan Tu, Guodong Wu, Xunqiang Wang, Xiao Jun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2024-204972

Published: 2024

Journal Articles

Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Maria Latacz, Yansu Song, Yi Hao, Marta Cykowiak, Julia Kirylczuk, Jing Hu, Bi Shi, Hao Jiang

Blood (2024) 144 (Supplement 1): 42.

https://doi.org/10.1182/blood-2024-204634

Published: 2024

Journal Articles

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Zhenkun Wang, Zhi-Wei Zhang, Zhong-Shi Lyu, Tong Xing, Mi Liang, Mengzhu Shen, Chen-Yuan Li, Xin-Yan Zhang, Dan-Dan Chen, Ya-Zhe Wang, Li-Juan Hu, Hao Jiang, Qian Jiang, Yuan Kong, Xiao-Jun Huang

Blood (2024) 144 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2024-201354

Published: 2024

Journal Articles

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Menglin Li, Yi-Meng Li, Qingyuan Qu, Yuxiu Chen, Jianying Zhou, Mengyu Xiao, Chencong Wang, Qi Chen, Xiaolu Zhu, Yun He, YuanYuan Zhang, Qian Jiang, Hao Jiang, Jin Lu, YingJun Chang, Xiaosu Zhao, Xiangyu Zhao, Xiao Jun Huang, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2024-204777

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLT3-ITD drives poor prognosis in NPM1 mutated AML via BCAT1-dependent epigenetic regulation

IDH1/2 mutations predict a distinct high-risk subset in Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia

Thrombopoietin receptor agonists combined with intensive immunosuppressive therapy improve outcomes in elderly patients with severe aplastic anemia: A single-center retrospective study

Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Safety and efficacy of venetoclax plus CAG (cytarabine, aclarubicin, G-CSF) regimen in patients with relapsed or refractory Acute Myeloid Leukemia: A prospective single-arm phase II study

Oral etoposide vs intravenous daunorubicin plus ATRA-RIF as induction therapy for low-risk acute promyelocytic leukemia: A phase II randomized controlled Trial

Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia

Vennetoclax combined with decitabine, cytarabine, aclacinomycin and granulocyte colony-stimulating factor as induction regimen achieved high response rate in newly diagnosed adverse risk Acute Myeloid Leukemia

Oral VP16 combined with ATRA and realgar-indigo naturalis formula as complete oral induction regimen is an fast，safe and effective regimen during induction to reduce mortality in high-risk acute promyelocytic leukemia

Efficacy and safety results of TQB3909，a novel BCL-2 inhibitor, in combination with azacitidine for patients with myeloid malignancies

Integrating EVI1 expression into prognostic models for MDS: Insights from IPSS-R and IPSS-m subgroup analyses

Kte-X19 in relapsed or refractory adult B-cell acute lymphoblastic leukemia in the Chinese population: 6-month analysis of a phase II multicenter trial

Clinical efficacy and diagnostic value of metagenomic next-generation sequencing for pathogen detection in severe aplastic anemia patients with suspected infectious diseases

Hypoxia-driven complement activation expands circulating endothelial cells in transplant-associated thrombotic microangiopathy: A multi-omics single-cell and functional study

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Recurrent ASXL1 Mutations Promote Myeloid Malignancies through Unleashed Condensation

Inhibition of TGF-β in Bone Marrow Endothelial Progenitor Cells Promotes Hematopoietic Recovery in Acute Myeloid Leukemia after Chemotherapy

Clinical Features and Prognostic Nomogram for Therapy-Related Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only